CL2014003241A1 - Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. - Google Patents
Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar.Info
- Publication number
- CL2014003241A1 CL2014003241A1 CL2014003241A CL2014003241A CL2014003241A1 CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1 CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A CL2014003241 A CL 2014003241A CL 2014003241 A1 CL2014003241 A1 CL 2014003241A1
- Authority
- CL
- Chile
- Prior art keywords
- lpar
- antagonists
- pulmonary fibrosis
- acid receptor
- lysophosphatidic acid
- Prior art date
Links
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 title 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 208000005069 pulmonary fibrosis Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661953P | 2012-06-20 | 2012-06-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003241A1 true CL2014003241A1 (es) | 2015-03-20 |
Family
ID=48628669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003241A CL2014003241A1 (es) | 2012-06-20 | 2014-11-28 | Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20150133512A1 (en:Method) |
| EP (1) | EP2864301A1 (en:Method) |
| JP (1) | JP2015520203A (en:Method) |
| KR (1) | KR20150011389A (en:Method) |
| CN (1) | CN104395299A (en:Method) |
| AU (1) | AU2013279513A1 (en:Method) |
| BR (1) | BR112014030674A2 (en:Method) |
| CA (1) | CA2869564A1 (en:Method) |
| CL (1) | CL2014003241A1 (en:Method) |
| CO (1) | CO7131357A2 (en:Method) |
| EA (1) | EA201492281A1 (en:Method) |
| HK (1) | HK1206339A1 (en:Method) |
| IL (1) | IL236087A0 (en:Method) |
| IN (1) | IN2014DN09352A (en:Method) |
| MA (1) | MA37762B1 (en:Method) |
| MX (1) | MX2014014711A (en:Method) |
| PE (1) | PE20142305A1 (en:Method) |
| PH (1) | PH12014502363A1 (en:Method) |
| SG (1) | SG11201407228PA (en:Method) |
| UA (1) | UA110310C2 (en:Method) |
| WO (1) | WO2013189865A1 (en:Method) |
| ZA (1) | ZA201408167B (en:Method) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140067048A (ko) | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | 라이소포스파티드산 수용체 길항제 |
| US20140213538A1 (en) * | 2013-01-15 | 2014-07-31 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| AU2014232383B2 (en) | 2013-03-15 | 2019-01-17 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| UY36060A (es) | 2014-04-02 | 2015-10-30 | Bayer Pharma AG | Compuestos de azol sustituidos con amida |
| MX370408B (es) | 2014-06-27 | 2019-12-11 | Ube Industries | Sal de compuesto heterociclico sustituido con halogeno. |
| WO2017055316A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| WO2017055313A1 (en) | 2015-10-01 | 2017-04-06 | Bayer Pharma Aktiengesellschaft | Amido-substituted azole compounds |
| AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| WO2018078009A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives |
| WO2018078005A1 (en) | 2016-10-29 | 2018-05-03 | Bayer Pharma Aktiengesellschaft | Amido-substituted azaspiro derivatives as tankyrase inhibitors |
| WO2018087126A1 (en) | 2016-11-09 | 2018-05-17 | Bayer Pharma Aktiengesellschaft | Amido-substituted cyclohexane derivatives as inhibitors of tankyrase |
| CN107827829A (zh) * | 2017-11-07 | 2018-03-23 | 大连理工大学 | 5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑在水相及生物介质中的制备方法 |
| CN107721984A (zh) * | 2017-11-07 | 2018-02-23 | 大连理工大学 | 一种新型5‑酰胺基‑1,4,5‑三取代的1,2,3‑三氮唑的制备方法 |
| WO2019126084A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EP3728196B1 (en) | 2017-12-19 | 2023-04-05 | Bristol-Myers Squibb Company | Pyrazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| EP3728242B1 (en) * | 2017-12-19 | 2023-03-01 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| MX2020005323A (es) | 2017-12-19 | 2020-08-13 | Bristol Myers Squibb Co | Triazol azinas de acido ciclohexilo como antagonistas de acido lisofosfatidico (lpa). |
| CA3085347A1 (en) | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| CN111479807B (zh) * | 2017-12-19 | 2024-11-26 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸异噁唑吖嗪 |
| BR112020012177A2 (pt) | 2017-12-19 | 2020-11-24 | Bristol-Myers Squibb Company | azóis triazóis do ácido ciclo-hexílico como antagonistas de lpa |
| EP3728210A1 (en) | 2017-12-19 | 2020-10-28 | Bristol-Myers Squibb Company | Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| US11352345B2 (en) | 2017-12-19 | 2022-06-07 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azoles as LPA antagonists |
| KR102725744B1 (ko) | 2017-12-19 | 2024-11-01 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 시클로헥실 산 피라졸 아진 |
| ES2946657T3 (es) | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434653A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 三氮唑类化合物及其制备方法与用途 |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| US11980609B2 (en) | 2021-05-11 | 2024-05-14 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| EP4444707A1 (en) | 2021-12-08 | 2024-10-16 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| CN115745848A (zh) * | 2022-12-07 | 2023-03-07 | 上海优合生物科技有限公司 | 一种氨基胍的加工合成工艺 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) * | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| EA201390821A1 (ru) * | 2010-12-07 | 2013-10-30 | Амира Фармасьютикалс, Инк. | Антагонисты рецепторов лизофосфатидной кислоты и их применение |
| WO2012138648A1 (en) * | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| KR20140067048A (ko) * | 2011-08-15 | 2014-06-03 | 인터뮨, 인크. | 라이소포스파티드산 수용체 길항제 |
| WO2013189864A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
-
2013
- 2013-06-17 CN CN201380031806.0A patent/CN104395299A/zh active Pending
- 2013-06-17 AU AU2013279513A patent/AU2013279513A1/en not_active Abandoned
- 2013-06-17 UA UAA201500426A patent/UA110310C2/uk unknown
- 2013-06-17 MX MX2014014711A patent/MX2014014711A/es unknown
- 2013-06-17 PE PE2014002213A patent/PE20142305A1/es not_active Application Discontinuation
- 2013-06-17 CA CA2869564A patent/CA2869564A1/en not_active Abandoned
- 2013-06-17 HK HK15106924.1A patent/HK1206339A1/xx unknown
- 2013-06-17 US US14/403,261 patent/US20150133512A1/en not_active Abandoned
- 2013-06-17 JP JP2015517705A patent/JP2015520203A/ja active Pending
- 2013-06-17 KR KR1020147035551A patent/KR20150011389A/ko not_active Ceased
- 2013-06-17 EP EP13729332.0A patent/EP2864301A1/en not_active Withdrawn
- 2013-06-17 MA MA37762A patent/MA37762B1/fr unknown
- 2013-06-17 IN IN9352DEN2014 patent/IN2014DN09352A/en unknown
- 2013-06-17 EA EA201492281A patent/EA201492281A1/ru unknown
- 2013-06-17 WO PCT/EP2013/062463 patent/WO2013189865A1/en active Application Filing
- 2013-06-17 BR BR112014030674A patent/BR112014030674A2/pt not_active Application Discontinuation
- 2013-06-17 SG SG11201407228PA patent/SG11201407228PA/en unknown
-
2014
- 2014-10-22 PH PH12014502363A patent/PH12014502363A1/en unknown
- 2014-11-07 ZA ZA2014/08167A patent/ZA201408167B/en unknown
- 2014-11-20 CO CO14255124A patent/CO7131357A2/es unknown
- 2014-11-28 CL CL2014003241A patent/CL2014003241A1/es unknown
- 2014-12-04 IL IL236087A patent/IL236087A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA110310C2 (uk) | 2015-12-10 |
| US20150133512A1 (en) | 2015-05-14 |
| MA37762B1 (fr) | 2018-04-30 |
| EA201492281A1 (ru) | 2015-04-30 |
| PE20142305A1 (es) | 2015-01-16 |
| HK1206339A1 (en) | 2016-01-08 |
| EP2864301A1 (en) | 2015-04-29 |
| PH12014502363A1 (en) | 2015-01-12 |
| CN104395299A (zh) | 2015-03-04 |
| JP2015520203A (ja) | 2015-07-16 |
| AU2013279513A1 (en) | 2014-10-16 |
| WO2013189865A1 (en) | 2013-12-27 |
| CA2869564A1 (en) | 2013-12-27 |
| SG11201407228PA (en) | 2014-12-30 |
| IN2014DN09352A (en:Method) | 2015-07-17 |
| ZA201408167B (en) | 2015-12-23 |
| MA37762A1 (fr) | 2017-07-31 |
| CO7131357A2 (es) | 2014-12-01 |
| IL236087A0 (en) | 2015-02-01 |
| BR112014030674A2 (pt) | 2017-06-27 |
| KR20150011389A (ko) | 2015-01-30 |
| MX2014014711A (es) | 2015-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2014003241A1 (es) | Compuestos de n-ariltriazol como antagonistas del receptor de acido lisofosfatidico (lpar); y su uso contra la fibrosis pulmonar. | |
| CL2014003243A1 (es) | Compuestos de n-alquiltriazol como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra fibrosis pulmonar. | |
| IL277652B (en) | Stable aqueous formulations of adlimumab | |
| CL2014003242A1 (es) | Compuestos de pirazol sustituidos como antagonistas del receptor del acido lisofosfatidico (lpar); usos contra la fibrosis pulmonar. | |
| DK2882850T3 (da) | System for preparation of adipose-derived stem cells | |
| EP2903509A4 (en) | PORTABLE HEART MONITOR | |
| IL230913A0 (en) | Lysophosphatidic acid receptor antagonists | |
| IL226491A0 (en) | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | |
| CO7061086A2 (es) | Combinaciones de compuestos activos | |
| CL2014003031A1 (es) | Compuestos derivados de uracilo sustituidos biciclicamente; procedimiento de preparacion; composicion farmaceutica; uso para tratar y/o prevenir insuficiencia cardiaca, hipertension pulmonar, epoc, asma, nefropatia, entre otras. | |
| HRP20160250T1 (hr) | Postupak za pripravu 2-(2,3-dimetilfenil)-1-propanala s kloracetonom | |
| IL236688B (en) | Beta amino acid derivatives as integrin antagonists | |
| EP2925325A4 (en) | STABILIZED FORMULATION OF PEMETREXED | |
| DK2869854T3 (da) | Sammensætning omfattende ectoin eller hydroxyectoin som en aktiv substans til at fremme regenereringen af beskadiget kropsvæv | |
| CO6950497A2 (es) | Compuestos de 1,2,5-oxadiazol sustituidos y su uso como herbicidas | |
| CR20140263A (es) | Composicion herbicida que contiene acido de 4-amino-3-cloro-6-(-4-cloro-2-fluor-3-metoxifenil) piridina-2-carboxilico, o los derivados del mismo y fluroxipir, o los derivados del mismo | |
| BR112013012452A2 (pt) | uso de dispersões aquosas como primers | |
| CL2015001399A1 (es) | Composiciones detergentes acuosas de estructura polimérica. | |
| SMT201500296B (it) | Antagonisti del recettore trpm8 | |
| CR20140343A (es) | Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina | |
| ZA201600753B (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| BR112014010153A2 (pt) | formulação esporicida, lenço e lenço umedecido | |
| BR112013009640A2 (pt) | derivados de tetrahidroquinolina usados como ativadores de ampk | |
| ZA201500979B (en) | Electrochemical generation of chlorinated urea derivatives | |
| EP2888261A4 (en) | ANTAGONISTS OF CHEMOKIN RECEPTORS |